Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Average Recommendation of “Hold” by Brokerages

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has earned an average rating of “Hold” from the five ratings firms that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $4.50.

MIST has been the subject of a number of research reports. Wells Fargo & Company initiated coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, September 11th. They set an “overweight” rating and a $4.00 target price for the company. HC Wainwright upgraded shares of Milestone Pharmaceuticals to a “buy” rating and set a $5.00 price objective on the stock in a report on Thursday, June 5th.

Milestone Pharmaceuticals Trading Down 0.5%

NASDAQ:MIST opened at $1.94 on Thursday. Milestone Pharmaceuticals has a one year low of $0.63 and a one year high of $2.75. The company has a debt-to-equity ratio of 4.06, a current ratio of 4.97 and a quick ratio of 4.97. The firm has a market capitalization of $164.88 million, a price-to-earnings ratio of -2.31 and a beta of 0.60. The business has a fifty day moving average price of $1.68 and a 200-day moving average price of $1.56.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). Sell-side analysts forecast that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Hedge Funds Weigh In On Milestone Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bay Rivers Group purchased a new stake in shares of Milestone Pharmaceuticals during the second quarter worth about $28,000. Creative Planning lifted its position in Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after buying an additional 10,000 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Milestone Pharmaceuticals during the fourth quarter worth $73,000. Raymond James Financial Inc. raised its holdings in Milestone Pharmaceuticals by 30.1% in the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock valued at $84,000 after acquiring an additional 10,000 shares in the last quarter. Finally, XTX Topco Ltd raised its holdings in Milestone Pharmaceuticals by 52.7% in the first quarter. XTX Topco Ltd now owns 52,004 shares of the company’s stock valued at $42,000 after acquiring an additional 17,950 shares in the last quarter. Institutional investors and hedge funds own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.